Baiteng Zhao Acquires 38,040 Shares of WHWK
Baiteng Zhao has purchased 38,040 shares of WHWK, trading at $4.16.
Key Points
- Baiteng Zhao purchased 38,040 shares of WHWK on June 12, 2026.
- WHWK shares are trading at $4.16 with peer institutions holding substantial positions.
- Analysts from Citizens and Jones Trading have set buy ratings with targets of $8 and $7 respectively.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Baiteng Zhao recently added 38,040 shares of WHWK to his portfolio on June 12, 2026. The transaction did not specify a purchase price, but WHWK shares are currently trading around $4.16.
Other Institutional Activity in WHWK
Several institutional investors maintain significant holdings in WHWK. QVT Financial LP holds 4,615,709 shares valued at about $15.9 million. Similarly, Orbimed Advisors LLC has 4,166,000 shares worth approximately $14.4 million. Suvretta Capital Management, LLC owns 3,700,000 shares valued at $12.8 million, while Acuta Capital Partners, LLC holds 3,410,402 shares totaling $11.8 million. Lastly, Avoro Capital Advisors LLC possesses 2,849,402 shares worth nearly $9.8 million.
Whitehawk Therapeutics, Inc. Stock Down 10.0%
Shares of WHWK trade near $4.16. The stock's recent activity is supported by substantial institutional holdings, indicating a level of interest from major investors.
$WHWK stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at Whitehawk Therapeutics, Inc.
On June 12, 2026, multiple insiders including Castelein Caley, Desai Neil, Reeve Emma, Maroun Richard, Zhao Baiteng, and Aghazadeh Behzad each purchased 38,040 shares of WHWK. These transactions were not part of any pre-planned trading programs.
Analysts Set New Price Targets
On April 16, 2026, Citizens initiated coverage on WHWK with a 'buy' rating and a price target of $8. Previously, on December 22, 2025, Jones Trading also initiated coverage with a 'buy' rating and a $7 price target. The consensus among analysts is positive, with a general recommendation to buy.
Bottom Line
The recent insider buying activity at WHWK, including Baiteng Zhao's acquisition, highlights interest in the company. With WHWK shares trading at $4.16 and analysts setting higher price targets, investors are paying close attention. It's important to remember that filings such as these are backward-looking and may not reflect the current position.
Get Whitehawk Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $WHWK, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.